News | December 22, 2011

First Canadian Patient Receives Ovation Abdominal Stent Graft

December 22, 2011 — TriVascular Inc. announced the first Canadian patients treated with its Ovation Abdominal Stent Graft. The ultra-low profile (14F OD) system is designed to expand the patient population suitable for endovascular aortic repair (EVAR) by addressing a wider range of diseased anatomy. Cherrie Abraham, M.D., vascular surgery, McGill University, performed the first case in Canada at Montreal Jewish General Hospital (JGH). The second case, also performed at JGH, was performed by Daniel Obrand, M.D., chief of vascular surgery, JGH.

"The Ovation abdominal stent graft performed very well in the two cases completed here," said Abraham. "We are pleased to be in a position to offer this technology to patients that would otherwise not have a viable treatment option for their abdominal aortic aneurysms. The significantly reduced profile of the delivery catheter will increase the pool of patients to whom we can offer EVAR. This was our first aneurysm patient that has gone home on the same day as his surgery and may be the start of a new paradigm in vascular surgery: same day surgery for abdominal aortic aneurysm repair for select patients. I think the low profile grafts give us the confidence to send patients home sooner."

The device is available in Canada under Health Canada's Special Access Program (SAP). The program allows doctors to gain access to medical devices in emergency use cases or when conventional therapies have failed, are unavailable, or are unsuitable to treat a patient.

Ovation has been used to treat more than 500 patients worldwide. The device is approved for use by the U.S. Food and Drug Administration (FDA) under a Humanitarian Device Exemption (HDE). In Europe, it is CE marked and is used to treat a broad range of patients with abdominal aortic aneurysms.

For more information: www.trivascular.com

Related Content

FDA Grants Breakthrough Device Designation for Valiant Thoracoabdominal Aortic Aneurysm Stent Graft
News | Stent Grafts | October 09, 2019
Medtronic plc announced it has received Breakthrough Device designation from the U.S. Food and Drug Administration (FDA...
PQ Bypass Granted IDE Approval to Start TORUS SFA Stent Graft Pivotal Study
News | Stent Grafts | October 08, 2019
PQ Bypass Inc. announced it has received full approval of its investigational device exemption (IDE) trial of the...
First U.S. Patient Receives Gore Tag Conformable Thoracic Stent Graft With Active Control
News | Stent Grafts | July 10, 2019
W. L. Gore & Associates Inc. (Gore) announced the first U.S. implant of the Gore Tag Conformable Thoracic Stent...
Gore Receives FDA Approval for Gore Tag Conformable Thoracic Stent Graft
Technology | Stent Grafts | May 15, 2019
W. L. Gore & Associates Inc. (Gore) announced the U.S. Food and Drug Administration (FDA) has granted regulatory...
Aortic Stent Graft Global Market to Reach $5.4 Billion by 2028
News | Stent Grafts | February 14, 2019
Abdominal aortic stent grafts will remain the largest segment in the global aortic stent graft market at least through...
Medtronic Receives FDA Approval for Valiant Navion Thoracic Stent Graft System
Technology | Stent Grafts | February 07, 2019
Medtronic plc recently received U.S. Food and Drug Administration (FDA) approval for the Valiant Navion thoracic stent...
Endologix Ends Unrestricted Sales and Use of Nellix System
News | Stent Grafts | January 07, 2019
January 7, 2019 — Endologix Inc.
Endologix Reports Positive One-Year Results From the Ovation LUCY Study
News | Stent Grafts | July 16, 2018
Endologix Inc. announced one-year results from the LUCY (Evaluation of FemaLes who are Underrepresented Candidates for...
FDA Committee Votes in Favor of Incraft AAA Stent Graft System
News | Stent Grafts | June 13, 2018
Cardinal Health announced that its Incraft Abdominal Aortic Aneurysm (AAA) Stent Graft System has received a favorable...
First Patient Enrolled in Gore Excluder Investigational Study
News | Stent Grafts | January 08, 2018
January 8, 2018 — W. L. Gore & Associates Inc.